Stay updated with breaking news from Douglast Ross. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OncoCyte Co. (NYSEAMERICAN:OCX – Get Rating) insider Douglas T. Ross bought 15,000 shares of OncoCyte stock in a transaction on Friday, March 25th. The stock was acquired at an average price of $1.40 per share, for a total transaction of $21,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible […]
Message : Required fields Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT IRVINE, Calif., April 10, 2021...